MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical
company specializing in innovative therapies to address unmet needs
in severe burn and wound management, announces that a “
Meet
the Expert” panel chaired by SunTrust Robinson Humphrey
and comprised of leading burn specialists from around the world
will be convened at the upcoming 49th American Burn Association
Annual Meeting (ABA) on March 22nd at 5:45 p.m. Eastern time.
The ABA is taking place March 21-24, 2017 in Boston.
Investors and other interested parties can
access the panel discussion by dialing (877) 602-7189 (U.S.) or
(678) 894-3057 (International) and entering pass-code 90467501. The
audio of the panel discussion will be broadcast live on the
Internet at www.mediwound.com, where it will also be archived for
90 days. A telephone replay of the panel discussion will be
accessible two hours after its completion until 7:00 p.m. Eastern
time March 29, 2017 by dialing (855) 859-2056 (U.S.) or (404)
537-3406 and entering pass-code 90467501.
The panel discussion will be chaired by SunTrust
Robinson Humphrey’s Senior Analyst, Bruce Nudell, PhD, and will
share outcomes from the growing use of NexoBrid® throughout Europe
for the debridement of severe burns, as well as provide insight on
the future integration of NexoBrid as part of the U.S.
standard-of-care. The panel will include the following
leading burn experts:
- Jeremy Goverman, MD, Division of Burns, Massachusetts General
Hospital (Boston, Mass.)
- José Ramón Martínez-Mendez, MD, Department of Plastic and
Reconstructive Surgery and Burn Center, Hospital Universitario La
Paz (Madrid, Spain)
- Ilaria Mataro, MD, Department of Plastic and Reconstructive
Surgery and Burn Center, Cardarelli Hospital (Naples, Italy)
- Stan Monstrey, MD, PhD, Department of Plastic and
Reconstructive Surgery and Burn Center, Ghent University Hospital
(Gent, Belgium)
- Frank Sander, MD, Department of Plastic and Reconstructive
Surgery and Burn Center, Unfallkrankenhaus Trauma Hospital Berlin
(Berlin, Germany)
“We are very excited to have these
internationally prominent burns specialists share their extensive
clinical experience using NexoBrid to treat their severe burn
patients and address live questions from investors and other
interested parties. We are particularly pleased with the
prominence of the participants, each a renowned burn care leader in
their country, as well as with the diversity of countries and
institutions represented. We believe these various
perspectives will provide a valuable exchange of information and
insight on how NexoBrid has been transforming burn care throughout
Europe and what impact the experts believe NexoBrid is likely to
have on the U.S. standard-of-care,” stated Gal Cohen, President and
Chief Executive Officer of MediWound. “We thank the burn
specialists in the panel for making themselves accessible to the
audience and to SunTrust for initiating and moderating the event.
We look forward to an engaging discussion and to continuing our
work in expanding access to NexoBrid to patients with severe burns
around the world.”
About the American Burn
Association
The American Burn Association and its members
dedicate their efforts and resources to promoting and supporting
burn-related research, education, care, rehabilitation, and
prevention. The ABA has more than 3,500 members in the United
States, Canada, Europe, Asia, and Latin America. Members include
physicians, nurses, occupational and physical therapists,
researchers, social workers, firefighters, and hospitals with burn
centers. The ABA’s multidisciplinary membership enhances its
ability to work toward common goals with other organizations on
educational programs.
About NexoBrid
NexoBrid is an easy-to-use, topically-applied
pharmaceutical product that removes dead or damaged tissue, known
as eschar, in four hours without harming the surrounding healthy
tissues. NexoBrid was granted marketing authorization from
the European Medicines Agency for the removal of eschar in adults
with deep partial and full-thickness thermal burns, and has been
launched in Europe and Israel. Representing a new paradigm in burn
care management, NexoBrid demonstrated in clinical studies, with
statistical significance, its ability to non-surgically and rapidly
remove the eschar earlier than other modalities, without harming
viable tissues. The removal of eschar or “debridement” is a
critical first step in the successful healing of severe burns and
chronic and other hard-to-heal wounds. With the current
standard-of-care (SOC), burn eschar is removed either with existing
topical agents that have been found to be minimally effective or
that take a significantly longer period of time to work, or by
resorting to non-selective surgery, which is traumatic and may
result in loss of blood and viable tissue.
About MediWound Ltd.
MediWound is a fully-integrated
biopharmaceutical company focused on developing, manufacturing and
commercializing novel therapeutics based on its patented
proteolytic enzyme technology to address unmet needs in the fields
of severe burns, chronic and other hard-to-heal wounds. MediWound’s
first innovative biopharmaceutical product, NexoBrid, received
marketing authorization from the European Medicines Agency as well
as the Israeli and Argentinian Ministries of Health, for removal of
dead or damaged tissue, known as eschar, in adults with deep
partial and full-thickness thermal burns and was launched in Europe
and Israel, with plans for a launch in Argentina.
NexoBrid represents a new paradigm in burn care management,
and clinical trials have demonstrated, with statistical
significance, its ability to non-surgically and rapidly remove the
eschar earlier and, without harming viable tissues.
MediWound's second innovative product, EscharEx®
is a topical biological drug being developed for debridement of
chronic and other hard-to-heal wounds and is complementary to the
large number of existing wound healing products, which require a
clean wound bed in order to heal the wound. EscharEx® contains the
same proteolytic enzyme technology as NexoBrid®, and benefits from
the wealth of existing development data on NexoBrid®. In two
Phase 2 studies, EscharEx® has demonstrated safety and efficacy in
the debridement of chronic and other hard-to-heal wounds, within a
few daily applications. For more information, please
visit www.mediwound.com.
Cautionary Note Regarding
Forward-Looking Statements
This release includes forward-looking statements
within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, Section 21E of the US Securities Exchange Act of
1934, as amended, and the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts, such as
statements regarding assumptions and results related to the
regulatory authorizations and launch dates. In some cases, you
can identify forward-looking statements by terminology such as
“believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “expect,” “predict,” “potential,” or the negative
of these terms or other similar expressions. Forward-looking
statements are based on MediWound’s current knowledge and its
present beliefs and expectations regarding possible future events
and are subject to risks, uncertainties and assumptions. Actual
results and the timing of events could differ materially from those
anticipated in these forward-looking statements as a result of
several factors. In particular, you should consider the risks
discussed under the heading “Risk Factors” in our annual report on
Form 20-F for the year ended December 31, 2016 and information
contained in other documents filed with or furnished to the
Securities and Exchange Commission. You should not rely upon
forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
future results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or will occur. The forward-looking statements made herein
speak only as of the date of this announcement and MediWound
undertakes no obligation to update publicly such forward-looking
statements to reflect subsequent events or circumstances, except as
otherwise required by law.
Contacts:
Anne Marie FieldsSharon
Malka
Senior Vice PresidentChief Financial and Operations
Officer
LHAMediWound
212-838-3777ir@mediwound.co.il
afields@lhai.com
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Sep 2023 to Sep 2024